Defining Potency with Practical Assays to Satisfy Regulators
Revolutionize your Approach to Potency Assay Development to Confidently Align
with the Clinical Outcome & Regulatory Guidelines
The 2nd Cell Therapy Potency Assay gathered 100+ experts working to rationally design better potency assays to smooth the path to regulatory approval and minimize hold times with scientifically rigorous and informative potency measurements.
Whether you submitted your first IND or geared up towards BLA submission, this critical meeting of minds was your premier opportunity to join the likes of bluebird bio, Arsenal Bio, Takeda, Merck, Sana Biotechnology and more, to gain critical updates on regulatory interactions and unpick how industry peers are approaching potency assay development.
Leave this meeting equipped with industry insights to understand what potency assays are showing, develop practical, compatible, reproducible assays; and better characterize your cell therapy products for targeted, untargeted, allogeneic and autologous platforms in oncology and non-oncology indications.
View the 2023 Agenda Now:
View the speaker faculty,
full agenda details, partners
and partnership opportunities,
and how to access the best possible
rates all in one handy guide.
Who's Attending in 2023?
2023 Speakers Included:
Senior Scientist - Clinical Stage Analytical Development
Takeda Pharmaceutical Co. Ltd.
Vice President - Analytical Development & Product Lead
Director - Bioanalytical Sciences
Mariska ter Haak
Senior Director - Analytical Development
Head of Analytical Sciences
Tigen Pharma SA
“Very Interactive. It is a hot area that cell therapy companies are facing and the right time to host this event.”
Vice President of Cell Therapy, Nurix Therapeutics - 2022 Attendee
Team Discounts Available:
3 Passes - 10% Discount
4 Passes - 15% Discount
5+ Passes - 20% Discount